Rudin Glaucoma Prize winner announced

Article

Dr Daniel Stamer has been awarded the prestigious Lewis Rudin Glaucoma Prize 2012.

Dr Daniel Stamer has been awarded the prestigious Lewis Rudin Glaucoma Prize 2012.

The professor of ophthalmology at Duke Eye Centre, Duke University School of Medicine, Durham, North Carolina, USA, was selected by the New York Academy of Medicine to receive the prize this year. He was presented with the award for his insightful research on fostering a greater understanding of glaucoma.

Dr David Abramson, Chair of the Lewis Rudin Prize Selection Committee and Chief of Ophthalmic Oncology at Memorial Sloan-Kettering Cancer Centre, said, "Dr Stamer's discovery of a previously unrecognized signalling molecule that is important in normal and glaucoma eyes (nitrous oxide synthase) opens entirely new areas for research and treatment of the most common glaucomas worldwide."

Additionally, Dr Stamer is Editor-in-Chief of the Journal of Ocular Pharmacology & Therapeutics and is a member of the editorial boards for Investigative Ophthalmology and Visual Science and Experimental Eye Research.

For more information on the Lewis Rudin Glaucoma Prize please visit the official webpage.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Related Content
An image of the old town in Winterthur, Switzerland, showing buildings and clock towers. Image credit: ©bill_17 – stock.adobe.com

Winterthur, Switzerland welcomes second annual Winterthur Ophthalmology Symposium

Hattie Hayes
March 14th 2025
Article

After a successful inaugural WOS in 2024, the congress will feature new lectures and wetlabs in its sophomore year

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
Wooden blocks which say PHASE and a block at the end with the numbers 1/2. The last block is switching from 1 to 2. This represents a clinical trial moving through phases. Image credit: ©rabbitti – stock.adobe.com

First patient dosed in Phase 1/2 ASTRA study for Stargardt disease therapy SB-007 (SpliceBio)

Hattie Hayes
March 13th 2025
Article

SpliceBio continues to actively enroll patients in the ASTRA study and accompanying POLARIS trial

Figure. Slit-scanning in vivo confocal microscopy images of the corneal endothelium: A (left) demonstrates a healthy control cornea: Image of a normal corneal endothelium, showing a uniform hexagonal cell pattern with consistent cell density and no visible guttae or abnormalities (white solid arrowhead). B (right) shows FECD: Increased confluency of guttata, illustrating a more extensive presence of these structures. Images courtesy UCL/NIHR Moorfields Biomedical Research Centre.

Study links new gender and genetic factors to Fuchs Endothelial Corneal Dystrophy

Hattie Hayes
March 13th 2025
Article

A large-scale study indicates women are more likely to develop the inherited corneal condition

Left to Right – Back Row: Peter Holland, CEO, IAPB, H.E. Gladys Mokhawa, Permanent Representative of Botswana to the United Nations, H.E Ambassador Walton Webson, Permanent Representative of Antigua and Barbuda to the United Nations &             Co-Chair and Founder of the UN Friends of Vision Group, Dr. A.H. Monjurul Kabir, Global Adviser and Team Leader, Gender Equality and Disability Inclusion, Mr. Werner Obermeyer, Director WHO, New York Front Row: Jennifer Gersbeck, Executive Director – Influence and Scaling Impact at The Fred Hollows Foundation and Co-Chair of the IAPB Gender Equity Work Group, HRH The Duchess of Edinburgh, Ms Tara Soomro, Permanent Mission of United Kingdom to the United Nations & Ambassador ECOSOC Affairs . Image courtesy of the International Agency for the Prevention of Blindness.

Her Royal Highness The Duchess of Edinburgh delivers keynote address on gender equity in eye care

Hattie Hayes
March 12th 2025
Article

The UN Friends of Vision group meeting coincided with International Women's Day and the UN Commission on the Status of Women

A person in scrubs holds their hand outstretched toward the camera. A digital overlay gives the impression that the doctor or clinician is offering information about the future of eye care and retinal health. Image credit: ©sdecoret – stock.adobe.com

Advanced therapies in neovascular AMD and DMO: Experts weigh in

Hattie Hayes
March 12th 2025
Article

A clinician panel illuminates current treatment paradigms and best practices for reducing treatment burden

© 2025 MJH Life Sciences

All rights reserved.